HK1179522A1 - Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine - Google Patents

Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine

Info

Publication number: HK1179522A1
Authority: HK; Hong Kong
Prior art keywords: lamivudine; dolutegravirabacvir; dolutegravir; abacavir; therapeutic combination
Prior art date: 2010-01-27

Application number

HK13106716.5A

Other languages

English (en)

Chinese (zh)

Inventor

Mark Richard Underwood

Original Assignee

Viiv Healthcare Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-27

Filing date

2013-06-06

Publication date

2013-10-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1179522(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-06 Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co

2013-10-04 Publication of HK1179522A1 publication Critical patent/HK1179522A1/xx

Links

UGWQMIXVUBLMAH-IVVFTGHFSA-N [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol;4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 UGWQMIXVUBLMAH-IVVFTGHFSA-N 0.000 title 1
RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 title 1
229960002542 dolutegravir Drugs 0.000 title 1
229960001627 lamivudine Drugs 0.000 title 1
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physiology (AREA)
Nutrition Science (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

HK13106716.5A 2010-01-27 2013-06-06 Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine HK1179522A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29858910P	2010-01-27	2010-01-27
PCT/US2011/022219 WO2011094150A1 (en)	2010-01-27	2011-01-24	Antiviral therapy

Publications (1)

Publication Number	Publication Date
HK1179522A1 true HK1179522A1 (en)	2013-10-04

Family

ID=44319704

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
HK13106716.5A HK1179522A1 (en)	2010-01-27	2013-06-06	Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine
HK15110408.8A HK1209629A1 (en)	2010-01-27	2013-06-06	Antiviral therapy
HK18109751.0A HK1250335A1 (zh)	2010-01-27	2013-06-06	抗病毒治療

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
HK15110408.8A HK1209629A1 (en)	2010-01-27	2013-06-06	Antiviral therapy
HK18109751.0A HK1250335A1 (zh)	2010-01-27	2013-06-06	抗病毒治療

Country Status (45)

Country	Link
US (13)	US20120295898A1 (xx)
EP (6)	EP3494972B1 (xx)
JP (8)	JP2013518107A (xx)
KR (4)	KR101883750B1 (xx)
CN (2)	CN105311033B (xx)
AP (1)	AP3551A (xx)
AU (1)	AU2011209788C1 (xx)
BR (1)	BR112012018670A2 (xx)
CA (4)	CA2787691C (xx)
CL (1)	CL2012002080A1 (xx)
CO (1)	CO6602152A2 (xx)
CR (1)	CR20120423A (xx)
CY (4)	CY1116509T1 (xx)
DK (4)	DK3127542T3 (xx)
DO (2)	DOP2012000205A (xx)
EA (4)	EA025176B1 (xx)
EC (1)	ECSP12012106A (xx)
ES (4)	ES2688925T3 (xx)
FI (2)	FI3494972T3 (xx)
FR (2)	FR18C1043I2 (xx)
HK (3)	HK1179522A1 (xx)
HR (4)	HRP20240168T1 (xx)
HU (6)	HUE026849T2 (xx)
IL (5)	IL221007A (xx)
LT (4)	LT3494972T (xx)
LU (1)	LUC00090I2 (xx)
MA (1)	MA34002B1 (xx)
ME (2)	ME03058B (xx)
MX (4)	MX356891B (xx)
MY (2)	MY202778A (xx)
NO (2)	NO2932970T3 (xx)
NZ (4)	NZ627827A (xx)
PE (2)	PE20121524A1 (xx)
PH (3)	PH12012501537A1 (xx)
PL (4)	PL3127542T3 (xx)
PT (4)	PT2531027E (xx)
RS (4)	RS57323B1 (xx)
SG (3)	SG10201707183TA (xx)
SI (4)	SI3127542T1 (xx)
SM (4)	SMT201800290T1 (xx)
TN (1)	TN2012000376A1 (xx)
TR (1)	TR201807704T4 (xx)
UA (1)	UA105556C2 (xx)
WO (1)	WO2011094150A1 (xx)
ZA (1)	ZA201205586B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS57323B1 (sr)	2010-01-27	2018-08-31	Viiv Healthcare Co	Antivirusna terapija
AU2013336491B2 (en)	2012-10-23	2018-08-02	Cipla Limited	Pharmaceutical antiretroviral composition
TWI752457B (zh)	2012-12-21	2022-01-11	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
EP2767272A1 (en) *	2013-02-18	2014-08-20	Ratiopharm GmbH	Solid pharmaceutical dosage form of dolutegravir
WO2014125124A1 (en) *	2013-02-18	2014-08-21	Ratiopharm Gmbh	Solid pharmaceutical dosage form of dolutegravir
US9421214B2 (en)	2013-07-12	2016-08-23	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (xx)	2013-07-12	2018-07-21
EA030695B1 (ru)	2013-09-27	2018-09-28	Мерк Шарп И Доум Корп.	Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
IN2014MU00916A (xx)	2014-03-20	2015-09-25	Cipla Ltd
CA2950911C (en)	2014-06-04	2023-10-10	Sanford-Burnham Medical Research Institute	Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh)	2014-06-20	2021-11-01	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (xx)	2014-06-20	2018-06-23
CA2956662A1 (en)	2014-07-29	2016-02-04	Lek Pharmaceuticals D.D.	Novel hydrates of dolutegravir sodium
TWI738321B (zh)	2014-12-23	2021-09-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
CA2980362C (en)	2015-04-02	2020-02-25	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3334419A1 (en) *	2015-08-14	2018-06-20	Sandoz AG	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) *	2016-05-27	2017-11-30	Viiv Healthcare Company	Combinations and uses treatments thereof
WO2018028841A1 (en) *	2016-08-12	2018-02-15	Sandoz Ag	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) *	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinations and uses and treatments thereof
EP3655106A4 (en) *	2017-07-18	2021-04-21	VIIV Healthcare Company	COMBINED INGREDIENTS THERAPY
US20200147092A1 (en) *	2017-07-21	2020-05-14	Viiv Healthcare Company	Regimens for treating hiv infections and aids
KR20200031658A (ko)	2017-07-21	2020-03-24	비이브 헬쓰케어 컴퍼니	Hib 감염 및 aids를 치료하기 위한 요법
KR20200070246A (ko) *	2017-10-13	2020-06-17	비이브 헬쓰케어 컴퍼니	이중층 제약 정제 제제
AU2020245350B2 (en)	2019-03-22	2023-04-20	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CN114901363A (zh) *	2020-01-09	2022-08-12	华盛顿大学	长效治疗剂组合物及其方法
US11697652B2 (en)	2020-02-24	2023-07-11	Gilead Sciences, Inc.	Tetracyclic compounds and uses thereof
EP4196479B9 (en)	2021-01-19	2024-10-16	Gilead Sciences, Inc.	Substituted pyridotriazine compounds and uses thereof
WO2023164293A1 (en) *	2022-02-28	2023-08-31	Jericho Sciences, Llc	Methods for viral infections
TWI843506B (zh)	2022-04-06	2024-05-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119202B1 (en)	1989-02-08	2006-10-10	Glaxo Wellcome Inc.	Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
ZA923641B (en)	1991-05-21	1993-02-24	Iaf Biochem Int	Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en)	1991-06-03	1991-07-24	Glaxo Group Ltd	Chemical compounds
GB9204015D0 (en)	1992-02-25	1992-04-08	Wellcome Found	Therapeutic nucleosides
US5663169A (en)	1992-08-07	1997-09-02	Merck & Co., Inc.	Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en)	1992-08-07	1997-11-20	Merck & Co Inc	Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en)	1994-02-04	1994-03-30	Wellcome Found	Chloropyrimidine intermediates
IL113432A (en)	1994-04-23	2000-11-21	Glaxo Group Ltd	Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk)	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій
MY115461A (en)	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US5849911A (en)	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
CO4900074A1 (es) *	1996-06-25	2000-03-27	Glaxo Group Ltd	Combinaciones antivirales
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en)	1997-02-05	1999-10-12	Merck & Co., Inc.	Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en)	1997-05-17	1997-07-09	Glaxo Group Ltd	A novel salt
US5935946A (en)	1997-07-25	1999-08-10	Gilead Sciences, Inc.	Nucleotide analog composition and synthesis method
GB9717928D0 (en)	1997-08-22	1997-10-29	Glaxo Group Ltd	Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en)	1997-10-14	1997-12-10	Glaxo Group Ltd	Process for the synthesis of chloropurine intermediates
US6436989B1 (en)	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
US6087383A (en)	1998-01-20	2000-07-11	Bristol-Myers Squibb Company	Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en)	1998-03-20	1998-05-13	Glaxo Group Ltd	Process for the sythesis of hiv protease inhibitors
EP1063888A1 (en)	1998-03-27	2001-01-03	The Regents of the University of California	Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk)	1998-04-07	2005-02-15	Брістол- Майєрс Сквібб Фарма Компані	Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) *	1998-04-29	1998-07-01	Glaxo Group Ltd	Pharmaceutical compositions
GB9815567D0 (en)	1998-07-18	1998-09-16	Glaxo Group Ltd	Antiviral compound
EP1255510B3 (en)	2000-01-31	2009-03-04	Cook Biotech, Inc.	Stent valves
CA2443449C (en)	2001-04-10	2008-11-04	Pfizer Inc.	Pyrazole derivatives for treating hiv
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) *	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
TW200403061A (en) *	2002-06-04	2004-03-01	Glaxo Group Ltd	Pharmaceutical compositions
EP1536800B1 (en) *	2002-06-27	2006-01-04	Medivir Ab	Synergistic interaction of abacavir and alovudine
EA015145B1 (ru) *	2003-01-14	2011-06-30	Джилид Сайэнс, Инк.	Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
BRPI0507628A (pt)	2004-02-11	2007-07-03	Smithkline Beecham Corp	composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
JP4285353B2 (ja)	2004-03-05	2009-06-24	清水建設株式会社	化学物質放散度評価方法
SI1742642T1 (sl) *	2004-04-14	2009-04-30	Gilead Sciences Inc	Fosfonatni analogi inhibitorskih spojin HIV integraze
US8633219B2 (en) *	2004-05-21	2014-01-21	Japan Tobacco Inc.	Combination therapy
US7176196B2 (en)	2004-05-28	2007-02-13	Bristol-Myers Squibb Company	Bicyclic heterocycles as HIV integrase inhibitors
WO2006024024A2 (en)	2004-08-23	2006-03-02	Teva Pharmaceutical Industries Ltd.	Solid and crystalline ibandronate sodium and processes for preparation thereof
WO2006024668A1 (en)	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
DK1799696T3 (da)	2004-09-17	2009-03-09	Idenix Pharmaceuticals Inc	Phosphoindoler som HIV-inhibitorer
US7250421B2 (en)	2005-01-31	2007-07-31	University Of Georgia Research Foundation, Inc.	Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
US20090093454A1 (en)	2005-03-04	2009-04-09	Kristjan Gudmundsson	Chemical Compounds
UA96568C2 (xx) *	2005-04-28	2011-11-25	Глаксосмиткляйн Ллк	Поліциклічне похідне карбамоїлпіридону як інгібор віл-інтегрази[полициклическое производное карбамоилпиридона как ингибитор вич-интегразы
EP2527007B1 (en)	2005-04-28	2016-03-30	VIIV Healthcare Company	Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
CA2610029A1 (en)	2005-06-01	2006-12-07	Bioalliance Pharma	Synergic combinations comprising a quinoline compound and other hiv infection therapeutic agents
UA108605C2 (uk) *	2005-12-30	2015-05-25		Спосіб покращення фармакокінетики інгібіторів інтегрази віл
JP4676536B2 (ja)	2005-12-30	2011-04-27	ギリアドサイエンシズ，インコーポレイテッド	Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法
MY150717A (en) *	2006-01-20	2014-02-28	Tibotec Pharm Ltd	Long term treatment of hiv-infection with tmc278
US20080039428A1 (en)	2006-06-29	2008-02-14	Panacos Pharmaceuticals, Inc.	Antiretroviral combination therapy
WO2008011117A2 (en)	2006-07-21	2008-01-24	Gilead Sciences, Inc.	Antiviral protease inhibitors
NZ575831A (en)	2006-09-29	2011-12-22	Idenix Pharmaceuticals Inc	Enantiomerically pure phosphoindoles as hiv inhibitors
PL2487161T5 (pl)	2007-02-23	2024-09-09	Gilead Sciences, Inc.	<div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div>
US20080241289A1 (en)	2007-02-23	2008-10-02	Auspex Pharmaceuticals, Inc.	Preparation and utility of non-nucleoside reverse transcriptase inhibitors
WO2009005693A1 (en)	2007-06-29	2009-01-08	Gilead Sciences, Inc.	Novel hiv reverse transcriptase inhibitors
CA2692460A1 (en)	2007-06-29	2009-01-08	Korea Research Institute Of Chemical Technology	Hiv reverse transcriptase inhibitors
EP2170851B1 (en)	2007-07-06	2013-09-04	Gilead Sciences, Inc.	Modulators of pharmacokinetic properties of therapeutics
CN101743006B (zh) *	2007-07-12	2013-09-11	泰博特克药品公司	(e)4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的晶型
WO2009058923A1 (en)	2007-10-31	2009-05-07	Smithkline Beecham Corporation	Ccr5 antagonists as therapeutic agents
EP2217573A4 (en)	2007-11-01	2011-08-31	Uab Research Foundation	TREATMENT AND PREVENTION OF VIRAL INFECTIONS
US8108055B2 (en)	2007-12-28	2012-01-31	Larry Wong	Method, system and apparatus for controlling an electrical device
AU2008342536A1 (en)	2008-01-03	2009-07-09	Virochem Pharma Inc.	Novel C-21-keto lupane derivatives preparation and use thereof
WO2009082819A1 (en) *	2008-01-03	2009-07-09	Virochem Pharma Inc.	Novel lupane derivatives
WO2009088719A1 (en)	2008-01-04	2009-07-16	Gilead Sciences, Inc.	Inhibitors of cytochrome p450
EP2257567A1 (en)	2008-02-14	2010-12-08	Virochem Pharma Inc.	Novel 17 beta lupane derivatives
WO2009148600A2 (en) *	2008-06-06	2009-12-10	Concert Pharmaceuticals, Inc.	Deuterated lysine-based compounds
PT2320908E (pt) *	2008-07-25	2014-03-06	Shionogi & Co	Pró-fármacos de dolutegravir
CN102245182B (zh)	2008-12-11	2014-07-23	盐野义制药株式会社	氨基甲酰基吡啶酮hiv整合酶抑制剂和中间体的合成
EP2376453B1 (en)	2008-12-11	2019-11-20	VIIV Healthcare Company	Intermediates for carbamoylpyridone hiv integrase inhibitors
RS57323B1 (sr)	2010-01-27	2018-08-31	Viiv Healthcare Co	Antivirusna terapija
GB201006038D0 (en)	2010-04-12	2010-05-26	Unilever Plc	Improvements relating to antiviral compositions
WO2011160024A2 (en)	2010-06-17	2011-12-22	Fuzians Biomedicals, Inc.	Compounds useful as antiviral agents, compositions, and methods of use
US20150094344A1 (en)	2011-04-01	2015-04-02	The Medicines Company	Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage

2011
- 2011-01-24 RS RS20180667A patent/RS57323B1/sr unknown
- 2011-01-24 NZ NZ627827A patent/NZ627827A/en unknown
- 2011-01-24 AU AU2011209788A patent/AU2011209788C1/en active Active
- 2011-01-24 EP EP19151897.6A patent/EP3494972B1/en active Active
- 2011-01-24 AP AP2012006445A patent/AP3551A/xx active
- 2011-01-24 PT PT117374843T patent/PT2531027E/pt unknown
- 2011-01-24 EP EP11737484.3A patent/EP2531027B1/en not_active Revoked
- 2011-01-24 US US13/575,380 patent/US20120295898A1/en not_active Abandoned
- 2011-01-24 SG SG10201707183TA patent/SG10201707183TA/en unknown
- 2011-01-24 CA CA2787691A patent/CA2787691C/en active Active
- 2011-01-24 MX MX2014014689A patent/MX356891B/es unknown
- 2011-01-24 DK DK16187411.0T patent/DK3127542T3/en active
- 2011-01-24 PL PL16187411T patent/PL3127542T3/pl unknown
- 2011-01-24 SM SM20180290T patent/SMT201800290T1/it unknown
- 2011-01-24 LT LTEP19151897.6T patent/LT3494972T/lt unknown
- 2011-01-24 EP EP15164931.6A patent/EP2932970B1/en not_active Revoked
- 2011-01-24 EP EP23214771.0A patent/EP4316599A3/en active Pending
- 2011-01-24 ES ES16187411.0T patent/ES2688925T3/es active Active
- 2011-01-24 SG SG2012053492A patent/SG182614A1/en unknown
- 2011-01-24 PE PE2012001082A patent/PE20121524A1/es active IP Right Grant
- 2011-01-24 CN CN201510619148.8A patent/CN105311033B/zh active Active
- 2011-01-24 SG SG10201509476RA patent/SG10201509476RA/en unknown
- 2011-01-24 PT PT16187411T patent/PT3127542T/pt unknown
- 2011-01-24 RS RS20150462A patent/RS54123B1/en unknown
- 2011-01-24 HR HRP20240168TT patent/HRP20240168T1/hr unknown
- 2011-01-24 NZ NZ627824A patent/NZ627824A/en unknown
- 2011-01-24 PH PH1/2012/501537A patent/PH12012501537A1/en unknown
- 2011-01-24 CA CA3003988A patent/CA3003988C/en active Active
- 2011-01-24 KR KR1020167025050A patent/KR101883750B1/ko active IP Right Grant
- 2011-01-24 FI FIEP19151897.6T patent/FI3494972T3/fi active
- 2011-01-24 ES ES11737484.3T patent/ES2543066T3/es active Active
- 2011-01-24 CA CA3060290A patent/CA3060290C/en active Active
- 2011-01-24 PT PT191518976T patent/PT3494972T/pt unknown
- 2011-01-24 SI SI201131593T patent/SI3127542T1/sl unknown
- 2011-01-24 SM SM20240063T patent/SMT202400063T1/it unknown
- 2011-01-24 EP EP18161536.0A patent/EP3351249A1/en not_active Withdrawn
- 2011-01-24 ES ES19151897T patent/ES2969969T3/es active Active
- 2011-01-24 WO PCT/US2011/022219 patent/WO2011094150A1/en active Application Filing
- 2011-01-24 KR KR1020127022254A patent/KR101830715B1/ko active IP Right Grant
- 2011-01-24 DK DK15164931.6T patent/DK2932970T3/en active
- 2011-01-24 PL PL19151897.6T patent/PL3494972T3/pl unknown
- 2011-01-24 NO NO15164931A patent/NO2932970T3/no unknown
- 2011-01-24 KR KR1020177017713A patent/KR20170078868A/ko active Application Filing
- 2011-01-24 RS RS20181178A patent/RS57728B1/sr unknown
- 2011-01-24 TR TR2018/07704T patent/TR201807704T4/tr unknown
- 2011-01-24 EA EA201290583A patent/EA025176B1/ru active Protection Beyond IP Right Term
- 2011-01-24 HU HUE11737484A patent/HUE026849T2/en unknown
- 2011-01-24 LT LTEP15164931.6T patent/LT2932970T/lt unknown
- 2011-01-24 PL PL15164931T patent/PL2932970T3/pl unknown
- 2011-01-24 EP EP16187411.0A patent/EP3127542B1/en active Active
- 2011-01-24 HU HUE19151897A patent/HUE065569T2/hu unknown
- 2011-01-24 CN CN201180015114.8A patent/CN102791129B/zh active Active
- 2011-01-24 MY MYPI2019000564A patent/MY202778A/en unknown
- 2011-01-24 MX MX2014014688A patent/MX367937B/es unknown
- 2011-01-24 LT LTEP16187411.0T patent/LT3127542T/lt unknown
- 2011-01-24 PL PL11737484T patent/PL2531027T3/pl unknown
- 2011-01-24 EA EA201690872A patent/EA032868B1/ru active Protection Beyond IP Right Term
- 2011-01-24 MY MYPI2012003346A patent/MY188334A/en unknown
- 2011-01-24 KR KR1020187018909A patent/KR101964923B1/ko active IP Right Grant
- 2011-01-24 HU HUE15164931A patent/HUE037812T2/hu unknown
- 2011-01-24 RS RS20240189A patent/RS65183B1/sr unknown
- 2011-01-24 SI SI201132101T patent/SI3494972T1/sl unknown
- 2011-01-24 PE PE2016000261A patent/PE20160180A1/es unknown
- 2011-01-24 ME MEP-2018-131A patent/ME03058B/me unknown
- 2011-01-24 SM SM20180594T patent/SMT201800594T1/it unknown
- 2011-01-24 DK DK11737484.3T patent/DK2531027T3/en active
- 2011-01-24 HU HUE16187411A patent/HUE040554T2/hu unknown
- 2011-01-24 DK DK19151897.6T patent/DK3494972T3/da active
- 2011-01-24 JP JP2012551213A patent/JP2013518107A/ja active Pending
- 2011-01-24 SI SI201131492T patent/SI2932970T1/en unknown
- 2011-01-24 SI SI201130539T patent/SI2531027T1/sl unknown
- 2011-01-24 ME MEP-2015-106A patent/ME02182B/me unknown
- 2011-01-24 UA UAA201209253A patent/UA105556C2/uk unknown
- 2011-01-24 PT PT151649316T patent/PT2932970T/pt unknown
- 2011-01-24 MX MX2014014687A patent/MX367938B/es unknown
- 2011-01-24 MA MA35145A patent/MA34002B1/fr unknown
- 2011-01-24 EA EA201892277A patent/EA037601B1/ru active Protection Beyond IP Right Term
- 2011-01-24 BR BR112012018670-1A patent/BR112012018670A2/pt not_active Application Discontinuation
- 2011-01-24 EA EA202190473A patent/EA202190473A3/ru unknown
- 2011-01-24 NZ NZ601319A patent/NZ601319A/en unknown
- 2011-01-24 NZ NZ627826A patent/NZ627826A/en unknown
- 2011-01-24 ES ES15164931.6T patent/ES2670811T3/es active Active
- 2011-01-24 CA CA2967453A patent/CA2967453C/en active Active
- 2011-01-24 MX MX2012008774A patent/MX2012008774A/es active IP Right Grant
2012
- 2012-07-18 DO DO2012000205A patent/DOP2012000205A/es unknown
- 2012-07-18 IL IL221007A patent/IL221007A/en active IP Right Grant
- 2012-07-24 ZA ZA2012/05586A patent/ZA201205586B/en unknown
- 2012-07-24 TN TNP2012000376A patent/TN2012000376A1/en unknown
- 2012-07-26 CO CO12125933A patent/CO6602152A2/es active IP Right Grant
- 2012-07-26 CL CL2012002080A patent/CL2012002080A1/es unknown
- 2012-08-13 CR CR20120423A patent/CR20120423A/es unknown
- 2012-08-14 EC ECSP12012106 patent/ECSP12012106A/es unknown
2013
- 2013-06-06 HK HK13106716.5A patent/HK1179522A1/xx not_active IP Right Cessation
- 2013-06-06 HK HK15110408.8A patent/HK1209629A1/xx unknown
- 2013-06-06 HK HK18109751.0A patent/HK1250335A1/zh unknown
2015
- 2015-05-13 US US14/710,952 patent/US20150238496A1/en not_active Abandoned
- 2015-07-14 HR HRP20150770TT patent/HRP20150770T1/hr unknown
- 2015-07-17 CY CY20151100633T patent/CY1116509T1/el unknown
- 2015-07-24 SM SM201500177T patent/SMT201500177B/xx unknown
2016
- 2016-01-28 PH PH12016500195A patent/PH12016500195B1/en unknown
- 2016-01-29 JP JP2016015242A patent/JP2016145204A/ja active Pending
- 2016-03-18 US US15/073,728 patent/US20160199379A1/en not_active Abandoned
- 2016-04-18 IL IL245182A patent/IL245182B/en active IP Right Grant
- 2016-08-01 US US15/224,865 patent/US20160339033A1/en not_active Abandoned
- 2016-08-22 JP JP2016161610A patent/JP6268386B2/ja active Active
- 2016-12-01 US US15/366,442 patent/US10426780B2/en active Active
- 2016-12-01 US US15/366,566 patent/US20170119777A1/en not_active Abandoned
2017
- 2017-04-19 US US15/490,944 patent/US20170216284A1/en not_active Abandoned
- 2017-06-13 US US15/620,859 patent/US20170281636A1/en not_active Abandoned
- 2017-12-12 US US15/838,738 patent/US20180098992A1/en not_active Abandoned
2018
- 2018-01-31 IL IL257267A patent/IL257267B/en active IP Right Grant
- 2018-03-15 US US15/922,240 patent/US20180200254A1/en not_active Abandoned
- 2018-04-05 JP JP2018072861A patent/JP2018127473A/ja active Pending
- 2018-05-23 CY CY20181100548T patent/CY1120457T1/el unknown
- 2018-05-30 HR HRP20180855TT patent/HRP20180855T1/hr unknown
- 2018-09-26 HR HRP20181531TT patent/HRP20181531T1/hr unknown
- 2018-10-15 NO NO2018036C patent/NO2018036I1/no unknown
- 2018-10-15 FR FR18C1043C patent/FR18C1043I2/fr active Active
- 2018-10-16 CY CY2018029C patent/CY2018029I1/el unknown
- 2018-10-22 LT LTPA2018013C patent/LTC2932970I2/lt unknown
- 2018-10-23 CY CY181101087T patent/CY1121040T1/el unknown
- 2018-10-26 HU HUS1800042C patent/HUS1800042I1/hu unknown
- 2018-10-31 LU LU00090C patent/LUC00090I2/en unknown
- 2018-11-26 PH PH12018502489A patent/PH12018502489A1/en unknown
2019
- 2019-06-07 JP JP2019106635A patent/JP2019167371A/ja active Pending
- 2019-06-26 IL IL267658A patent/IL267658B/en active IP Right Grant
2020
- 2020-03-31 US US16/835,733 patent/US11234985B2/en active Active
2021
- 2021-02-26 JP JP2021030306A patent/JP2021091705A/ja active Pending
- 2021-04-01 IL IL281959A patent/IL281959B/en unknown
- 2021-07-14 DO DO2021000147A patent/DOP2021000147A/es unknown
- 2021-09-08 US US17/468,794 patent/US20210401850A1/en not_active Abandoned
2022
- 2022-03-03 JP JP2022032464A patent/JP2022071126A/ja active Pending
2023
- 2023-04-04 JP JP2023060638A patent/JP2023085431A/ja active Pending
2024
- 2024-05-31 FI FIC20240016C patent/FIC20240016I1/fi unknown
- 2024-06-03 HU HUS2400017C patent/HUS2400017I1/hu unknown
- 2024-06-06 FR FR24C1024C patent/FR24C1024I1/fr active Active
- 2024-10-01 US US18/903,013 patent/US20250017939A1/en active Pending

Also Published As

Publication number	Publication date
RS65183B1 (sr)	2024-03-29
MY202778A (en)	2024-05-21
SMT202400063T1 (it)	2024-03-13
US10426780B2 (en)	2019-10-01
SI3494972T1 (sl)	2024-03-29
CY1121040T1 (el)	2019-12-11
HUE037812T2 (hu)	2018-09-28
SMT201800594T1 (it)	2019-01-11
US20170079982A1 (en)	2017-03-23
LT3127542T (lt)	2018-11-26
US11234985B2 (en)	2022-02-01
RS57728B1 (sr)	2018-12-31
CA3060290A1 (en)	2011-08-04
DOP2021000147A (es)	2022-01-16
EP2932970B1 (en)	2018-03-21
JP2016145204A (ja)	2016-08-12
US20170281636A1 (en)	2017-10-05
SMT201500177B (it)	2015-09-07
PE20160180A1 (es)	2016-05-04
ZA201205586B (en)	2014-01-29
US20180098992A1 (en)	2018-04-12
TR201807704T4 (tr)	2018-06-21
SG10201509476RA (en)	2015-12-30
CO6602152A2 (es)	2013-01-18
KR101883750B1 (ko)	2018-07-31
ME02182B (me)	2015-10-20
SG10201707183TA (en)	2017-10-30
PT2531027E (pt)	2015-09-16
AP3551A (en)	2016-01-18
IL257267A (en)	2018-03-29
EA025176B1 (ru)	2016-11-30
FI3494972T3 (fi)	2024-03-01
CA2787691C (en)	2018-07-17
PT3494972T (pt)	2024-02-12
US20170119777A1 (en)	2017-05-04
RS57323B1 (sr)	2018-08-31
SG182614A1 (en)	2012-08-30
CA3003988A1 (en)	2011-08-04
PL3127542T3 (pl)	2019-03-29
KR101964923B1 (ko)	2019-04-02
PT3127542T (pt)	2018-11-26
CN105311033A (zh)	2016-02-10
PL2531027T3 (pl)	2016-01-29
TN2012000376A1 (en)	2014-01-30
HUS1800042I1 (hu)	2018-11-28
SI2932970T1 (en)	2018-07-31
LUC00090I2 (xx)	2019-01-08
US20160339033A1 (en)	2016-11-24
UA105556C2 (uk)	2014-05-26
US20150238496A1 (en)	2015-08-27
ES2670811T3 (es)	2018-06-01
LTPA2018013I1 (lt)	2018-11-12
LT2932970T (lt)	2018-06-25
PH12016500195A1 (en)	2016-12-05
FR24C1024I1 (fr)	2024-07-26
IL257267B (en)	2019-08-29
EP2531027A4 (en)	2013-07-03
ES2969969T3 (es)	2024-05-23
PH12018502489A1 (en)	2020-06-15
HUE040554T2 (hu)	2019-03-28
SI2531027T1 (sl)	2015-08-31
MY188334A (en)	2021-11-30
ES2543066T3 (es)	2015-08-14
PL3494972T3 (pl)	2024-05-27
EA202190473A3 (ru)	2021-12-31
EP4316599A2 (en)	2024-02-07
HUE065569T2 (hu)	2024-06-28
EP2531027B1 (en)	2015-05-06
JP2021091705A (ja)	2021-06-17
HRP20150770T1 (hr)	2015-08-28
IL281959A (en)	2021-05-31
KR20180078358A (ko)	2018-07-09
DK2531027T3 (en)	2015-07-20
US20170216284A1 (en)	2017-08-03
IL245182A0 (en)	2016-06-30
CA2967453C (en)	2018-07-17
US20250017939A1 (en)	2025-01-16
US20210401850A1 (en)	2021-12-30
CY2018029I2 (el)	2019-07-10
HRP20240168T1 (hr)	2024-04-26
IL221007A (en)	2016-06-30
AP2012006445A0 (en)	2012-08-31
ES2688925T3 (es)	2018-11-07
MA34002B1 (fr)	2013-02-01
HK1209629A1 (en)	2016-04-08
JP2019167371A (ja)	2019-10-03
DOP2012000205A (es)	2012-10-15
JP2023085431A (ja)	2023-06-20
EA201290583A1 (ru)	2013-04-30
CN105311033B (zh)	2019-05-07
MX367938B (es)	2019-09-12
EA201690872A2 (ru)	2016-08-31
CA2787691A1 (en)	2011-08-04
SMT201800290T1 (it)	2018-07-17
IL267658A (en)	2019-08-29
EP2932970A1 (en)	2015-10-21
EP3127542A1 (en)	2017-02-08
EA032868B1 (ru)	2019-07-31
NZ627827A (en)	2016-02-26
FR18C1043I2 (fr)	2019-10-11
NO2932970T3 (xx)	2018-08-18
CL2012002080A1 (es)	2012-11-30
PE20121524A1 (es)	2012-12-03
IL245182B (en)	2018-04-30
KR101830715B1 (ko)	2018-04-04
JP6268386B2 (ja)	2018-01-31
EP3351249A1 (en)	2018-07-25
PL2932970T3 (pl)	2018-08-31
HUS2400017I1 (hu)	2024-06-28
MX2012008774A (es)	2012-08-17
PH12016500195B1 (en)	2021-08-04
FIC20240016I1 (fi)	2024-05-31
SI3127542T1 (sl)	2018-11-30
ECSP12012106A (es)	2013-05-31
HRP20181531T1 (hr)	2018-11-16
PT2932970T (pt)	2018-06-08
HUE026849T2 (en)	2016-08-29
WO2011094150A1 (en)	2011-08-04
HRP20180855T1 (hr)	2018-06-29
US20200230147A1 (en)	2020-07-23
EP3494972B1 (en)	2023-12-13
CY2018029I1 (el)	2019-07-10
KR20170078868A (ko)	2017-07-07
US20120295898A1 (en)	2012-11-22
EP3127542B1 (en)	2018-08-22
KR20120128640A (ko)	2012-11-27
DK3494972T3 (da)	2024-01-29
DK2932970T3 (en)	2018-05-28
MX367937B (es)	2019-09-12
ME03058B (me)	2019-01-20
NZ601319A (en)	2014-08-29
IL281959B (en)	2021-12-01
AU2011209788B2 (en)	2014-02-06
FR18C1043I1 (xx)	2018-11-30
CN102791129A (zh)	2012-11-21
IL221007A0 (en)	2012-09-24
JP2018127473A (ja)	2018-08-16
LT3494972T (lt)	2024-03-12
DK3127542T3 (en)	2018-11-12
CA2967453A1 (en)	2011-08-04
NZ627826A (en)	2016-01-29
LTC2932970I2 (lt)	2022-04-25
EP4316599A3 (en)	2024-04-10
EP2531027A1 (en)	2012-12-12
RS54123B1 (en)	2015-12-31
JP2022071126A (ja)	2022-05-13
US20180200254A1 (en)	2018-07-19
MX356891B (es)	2018-06-19
CY1116509T1 (el)	2017-03-15
CA3003988C (en)	2020-01-07
AU2011209788A1 (en)	2012-08-16
EA201690872A3 (ru)	2016-12-30
US20160199379A1 (en)	2016-07-14
EA037601B1 (ru)	2021-04-20
KR20160111536A (ko)	2016-09-26
EA201892277A1 (ru)	2019-03-29
CA3060290C (en)	2022-07-12
CN102791129B (zh)	2015-09-30
EA202190473A2 (ru)	2021-06-30
NZ627824A (en)	2016-02-26
HK1250335A1 (zh)	2018-12-14
JP2017008087A (ja)	2017-01-12
BR112012018670A2 (pt)	2018-02-06
NO2018036I1 (no)	2018-10-15
JP2013518107A (ja)	2013-05-20
AU2011209788C1 (en)	2014-08-28
CY1120457T1 (el)	2019-07-10
IL267658B (en)	2021-04-29
PH12012501537A1 (en)	2018-02-07
CR20120423A (es)	2012-11-22
EP3494972A1 (en)	2019-06-12

Publication	Publication Date	Title
HK1179522A1 (en)	2013-10-04	Therapeutic combination comprising dolutegravir, abacavir and lamivudine dolutegravirabacvir lamivudine
IL222481A0 (en)	2012-12-31	Combination therapy
EP2552323A4 (en)	2013-09-25	COMBINATION THERAPY
GB201005394D0 (en)	2010-05-12	Therapy
GB0905485D0 (en)	2009-05-13	Antiviral therapy
GB0916997D0 (en)	2009-11-11	Combination therapy
GB201011138D0 (en)	2010-08-18	Vaporiser
EP2629766A4 (en)	2014-05-14	COMBINATION THERAPY
GB0907973D0 (en)	2009-06-24	Combination therapy
GB0922098D0 (en)	2010-02-03	Therapeutic use
GB0903319D0 (en)	2009-04-08	Therapy
GB0921244D0 (en)	2010-01-20	Therapy
GB0903321D0 (en)	2009-04-08	Therapy
GB0914820D0 (en)	2009-09-30	WATerian therapy
GB0903145D0 (en)	2009-04-08	Medicaments uses and methods
GB0908952D0 (en)	2009-07-01	Antiviral therapy
GB0901902D0 (en)	2009-03-11	Medicament

Legal Events

Date	Code	Title	Description
2019-08-30	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20190124